PCV49 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT
May 1, 2011, 00:00
10.1016/j.jval.2011.02.236
https://www.valueinhealthjournal.com/article/S1098-3015(11)00375-5/fulltext
Title :
PCV49 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00375-5&doi=10.1016/j.jval.2011.02.236
First page :
A41
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
787